Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

3(42.9%)

Phase 4

3(42.9%)

Phase 2

1(14.3%)

7Total

N/A(3)

Phase 4(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06796920Not ApplicableRecruiting

Epidural Spinal Cord Stimulation for Lower-limb Impairment in Adrenomyeloneuropathy

Role: collaborator

NCT04860661Not ApplicableCompleted

Esketamine on Postpartum Depression in Cesarean Section Women

Role: collaborator

NCT03938311Not ApplicableUnknown

Time Window for Ischemic Stroke First Mobilization Effectiveness

Role: collaborator

NCT04279197Phase 2Completed

Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu

Role: collaborator

NCT04645407Phase 4Completed

Effects of Fuzheng Huayu Tablets on COVID-19

Role: collaborator

NCT02241590Phase 4Unknown

Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir

Role: collaborator

NCT02241616Phase 4Unknown

Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV

Role: collaborator

All 7 trials loaded